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Abstract A short enantioselective formal synthesis of the antibiotic
natural product platencin is reported. Key steps in the synthesis include
enantioselective decarboxylation alkylation, aldehyde/olefin radical cy-
clization, and regioselective aldol cyclization.
Key words formal synthesis, palladium, enantioselective reactions,
enantioconvergent synthesis, alkylation
The growing resistance of several pathogenic bacterial
strains against commercially available antibiotics necessi-
tates the rapid and efficient development of novel active in-
gredients. In this quest, natural products serve as valuable
lead structures.3 Recently, platencin (1, Figure 1)4 and plat-
ensimycin (2)5 were isolated by Merck scientists and deter-
mined to be highly active in vitro and in vivo antibiotics
possessing a novel mode of action. These natural products
attracted tremendous interest from the synthetic commu-
nity, and a number of different approaches to each natural
product have been reported.6,7 Herein, we disclose a short
and efficient enantioselective formal synthesis of platencin
(2) making use of enantioconvergent alkylation methodolo-
gy developed in our group.8
We have pursued a research strategy that consists of
identifying particular structural challenges of natural prod-
ucts to guide the development of novel methods in enantio-
selective catalysis.9 In accord with this tactic, we have de-
veloped a series of Pd-catalyzed enolate alkylation reac-
tions for the enantioselective synthesis of quaternary
stereocenters and applied these transformations in syn-
thetic studies toward several target molecules.10,11 The
presence of two all-carbon quaternary stereocenters in
both platencin (1) and platensimycin (2) entreated us to ex-
plore the synthesis of these molecules using our method.
We first chose to explore the synthesis of platencin (1) be-
cause of the interesting carbon framework that could be ac-
cessible through several different approaches. Since Nico-
laou6b and Rawal6c have reported procedures to introduce
the aromatic portion of the natural product, we targeted
tricyclic intermediate 3 (Scheme 1) for our synthetic stud-
ies. 
Initially, our retrosynthetic plan included the assembly
of the [2.2.2]bicyclic structure 4 by employing an intramo-
lecular vinyl radical cyclization12 of precursor 5 (Scheme 1).
We envisioned constructing dienone 5 through an intramo-
lecular aldol condensation with cyclohexanone 6. The abso-
lute stereochemistry of diketone 6 would be controlled via
Pd-catalyzed enantioconvergent alkylation using racemic
β-ketoester 7.
The necessary precursor for the projected asymmetric
alkylation was readily assembled through a three-step pro-
tocol (Scheme 2). Cyclohexanone (8) was converted into its
corresponding morpholine enamine13 that then reacted
with 2-chloroallyl chloroformate (9) to afford β-ketoester
10. Subsequent alkylation with ethyl vinyl ketone yielded
racemic alkylation precursor 7. Subsequent enantioconver-
gent decarboxylative alkylation reaction of chloro-substi-
tuted β-ketoester 7 in the presence of the complex derived
Figure 1  Structures of the antibiotics platencin (1) and platensimycin 
(2)
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1114,15 proceeded smoothly to provide cyclohexanone 6 in
85% yield. Interestingly, the related bromo-substituted β-
ketoester remained unreactive under identical reaction
conditions. We suspect that this is due to competitive oxi-
dative insertion of Pd into the C–Br bond, which precludes
the alkylation chemistry.
Scheme 2  Investigation of the asymmetric alkylation
Further synthetic manipulations toward our target in-
termediate 4 involved annulation of alkylation product 6 by
means of aldol cyclization (resulting in formation of bicyclic
enone 12, with a measured ee of 88%), followed by dehydro-
genation16 to afford dienone 5 (Scheme 2). Several reaction
conditions to effect the key cyclization to the bicy-
clo[2.2.2]octane 4 were examined, but none of these proved
successful. Application of radical conditions (Bu3SnH, AIBN,
benzene, 80 °C)17 led only to recovery of starting material,
while anionic conditions (t-BuLi, CuCN, THF, –78 °C)18 re-
sulted in the formation of a complex mixture of unidenti-
fied products.
To tackle the challenging synthesis of the chiral bicy-
clo[2.2.2]octane scaffold, we reconsidered our retrosynthet-
ic plan and decided to reverse the order of ring assembly
(Scheme 3). Postponing the aldol condensation to a later
stage in the synthesis, our focus shifted entirely towards
construction of the chiral bicyclo[2.2.2]octadione 13. We
envisioned an umpolung strategy in which aldehyde 14
would undergo an intramolecular conjugate addition (Stet-
ter cyclization).19 The aldehyde itself would again be the re-
sult of an enantioselective decarboxylative alkylation.
Scheme 3  Revised retrosynthesis of the platencin core
By following our revised strategy, the lithium enolate of
cyclohex-2-en-1-one (15) was treated with allyl diethyl-
phosphonoformate (16),20 an inexpensive alternative to
Mander’s reagent21 (Scheme 4). The intermediate β-keto-
ester 17 was then alkylated with ethyl vinyl ketone to afford
racemic substrate 18. The subsequent enantioselective de-
carboxylative alkylation reaction proceeded smoothly to
provide cyclohexenone 19 in good yield (88%) and 83% ee.
Selective oxidative cleavage of the more electron-rich dou-
ble bond in enone 19 was effected by ozone in the presence
of pyridine.22 However, when aldehyde 14 was subjected to
Stetter cyclization conditions promoted by thiazolium- or
triazolium-based catalysts,23 only the product of a benzoin-
type cyclization (20) was isolated.24 Given our recent suc-
cess with an aldehyde/olefin radical cyclization in another
synthetic effort,[11с] we exposed tricarbonyl compound 14
to the radical initiator V-40 (1,1′-azobis(cyclohexanecarbo-
nitrile)) and t-dodecanethiol in refluxing toluene. We were
delighted to find that the radical cyclization conditions pro-
vided the desired chiral bicyclo[2.2.2]octadione 13 in 78%
yield using this protocol.25
The key bridged bicycle 13 was then subjected to basic
conditions (KOH, MeOH, 23 °C, Scheme 5). These conditions
promoted an intramolecular aldol cyclization that appeared
to be completely regioselective for formation of the desired
tricyclic compound 21. Dione 21 was highly crystalline and
a single recrystallization from hexanes allowed us to in-
crease the enantiomeric excess to 99%. The structure of tri-
cycle 21 was confirmed by single-crystal X-ray diffraction
analysis (Figure 2).26
Scheme 1  Retrosynthetic analysis of platencin (1)
3
4
O
Cl
O
Cl
O
vinyl radical 
cyclization
aldol
condensation
enantioconvergent
alkylation
5
6
Platencin (1)
H
N
O
OH
OH
HO2C
O
H
O
H
O
5
O
Cl
O
O
7 O
O
Cl
O
1. morpholine, PhH
    Dean–Stark, Δ
2.
3. ethyl vinyl ketone
    K2CO3, acetone
    50 °C
O
O
Cl 9
Pd2(dba)3 (2.5 mol%)
THF, 30 °C
85% yield
Cl O
O
7
O
O
Cl
8
N
O
t-Bu
Ph2P
(6.25 mol %)
6
O
Cl
5
O
Cl
12 (88% ee)
KOH
CH3OH
23 °C
76% yield
69% yield (3 steps)
chloranil
t-BuOH, Δ
29% yield
O
Cl
O
11
4
O
O
O
enantioconvergent
alkylation
O
aldol
condensation
O
O
O
conjugate addition
olefination
13 14© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2018, 50, 4359–4368
4361
C. Defieber et al. PaperSyn thesis
D
ow
nl
oa
de
d 
by
: C
al
ifo
rn
ia
 In
st
itu
te
 o
f T
ec
hn
ol
og
y 
(C
AL
TE
CH
). C
op
yri
gh
ted
 m
ate
ria
l.Figure 2  ORTEP plot of dione 21 derived from X-ray crystallographic 
analysis (non-hydrogen atoms are shown with ellipsoids at 50% proba-
bility)
Chemoselective methylenation of the unconjugated ke-
tone moiety of 21 was achieved in 89% yield by action of a
Wittig reagent (Scheme 5). Exposure of the resulting alkene
(4) to Li metal led to enone reduction with concomitant for-
mation of a lithium enolate that was trapped with allyl bro-
mide to provide ketones 22 and 23 as a 1:1 mixture of dias-
tereomers. The configuration at C(9) is presumably set prior
to alkylation, but with poor stereoinduction from the bicy-
clic system. This C(9) configuration then exerts strong con-
trol over the subsequent alkylation. This was confirmed by
carrying out an analogous transformation quenching with
MeI in place of allyl bromide, which also delivered a 1:1
mixture of C(9) epimers. This reductive alkylation has pro-
vided variable yields (up to ca. 85%), but reproducibly re-
turns yields of ca. 25% in most cases. Extensive optimiza-
tion has not been pursued, however, although we observed
no variability in the diastereoselectivity. The enone func-
tionality present in the target structure (3) was introduced
by means of a silyl enol ether. After this oxidation, it was
possible to separate the diastereomers chromatographically
to isolate both the desired compound 3 (32% yield) and the
diastereomeric compound 24 (31% yield) in pure form. As
compound 3 is an intermediate in Nicolaou’s total synthesis
of platencin (1),6a this work constitutes a formal synthesis
of the natural product.
Scheme 5  Formal synthesis of platencin (1)
In conclusion, we have developed a short enantioselec-
tive formal synthesis of the antibiotic platencin (1). Key fea-
tures include the enantioconvergent catalytic alkylation to
set the absolute configuration of the key all-carbon quater-
nary center, as well as a radical-mediated cyclization to as-
semble the core bicyclo[2.2.2]octane structure.
Unless otherwise stated, reactions were performed in oven-dried
glassware using anhydrous, deoxygenated solvents under an atmo-
sphene of dry nitrogen. Anhydrous dichloromethane (CH2Cl2), hep-
tane, triethylamine (Et3N), tetrahydrofuran (THF) (BHT-free) were
purchased from Fisher or VWR, degassed with argon, and dried by
passage through activated drying columns27 on a Pure Process Tech-
nology system. Diisopropylamine was distilled from NaH immediate-
ly prior to use. Tris(dibenzylideneacetone)dipalladium(0)
[Pd2(dba)3]28 and (S)-t-BuPHOX8a,15,29 were synthesized according to
standard procedures and stored in a glovebox until immediately be-
fore use. All commercially obtained reagents were purchased from
Sigma–Aldrich, Alfa Aesar, Oakwood Chemical, or Fisher Scientific
and used as received. Reaction temperatures were controlled by an
IKAmag temperature modulator. Thin-layer chromatography (TLC)
was performed using E. Merck silica gel 60 F254 precoated plates
(0.25 mm) or Silicycle silica gel 60 F254 precoated plates (0.25 mm)
and visualized by UV fluorescence quenching, p-anisaldehyde, or KM-
nO4 staining. Flash chromatography30 was performed using either
Scheme 4  Assembly of the bicyclo[2.2.2]octadione scaffold
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l.SilicycleSiliaFlash® P60 silica gel (40–63 μm particle size) or ICN Sili-
ca gel (particle size 0.032–0.063 mm). Analytical chiral HPLC was per-
formed with an Agilent 1100 Series HPLC utilizing Chiralpak AD or
Chiralcel OD-H columns (4.6 mm × 25 cm) obtained from Daicel
Chemical Industries, Ltd. with visualization at 254 nm. Optical rota-
tions were measured with a Jasco P-1010 polarimeter at 589 nm.
Deuterated chloroform (CDCl3, 99.9%, extra dry) was purchased from
Cambridge Isotope Laboratories, Inc. and was used without further
purification. 1H and 13C NMR spectra were recorded with a Bruker
Avance DRX-500 (at 500 and 126 MHz, respectively) or DPX-400 in-
strument (at 400 and 101 MHz, respectively) or on a Varian Mercury
300 (at 300 MHz and 75 MHz, respectively) or Inova 500 (at 500 MHz
and 125 MHz, respectively) and are reported relative to Me4Si (δ =
0.0 ppm). Data for 1H NMR spectra are reported as follows: chemical
shift (δ, ppm) (multiplicity, coupling constant (Hz), integration). Mul-
tiplicities are reported as follows: s = singlet, d = doublet, t = triplet,
q = quartet, sept = sept, m = multiplet, comp. m = complex multiplet,
app. = apparent, br s = broad singlet. Data for 13C NMR spectra are re-
ported in terms of chemical shift relative to Me4Si (δ = 0.0 ppm). IR
spectra were recorded with either a Perkin Elmer Paragon 1000 or
Nicolet iS5 FTIR spectrometer and are reported in terms of frequency
of absorption (cm–1). High-resolution mass spectra were obtained ei-
ther from the California Institute of Technology Mass Spectral Facility
or the University of Illinois at Urbana–Champaign Mass Spectral Facil-
ity. Crystallographic data have been deposited at the CCDC, 12 Union
Road, Cambridge CB2 1EZ, UK, and copies can be obtained on request,
free of charge, by quoting the publication citation and the deposition
number.
2-Chloroallyl Chloroformate (9)
A 50 mL three-neck round-bottom flask equipped with a 25 mL addi-
tion funnel, a stir bar, and three septa was flame-dried under vacuum.
After refilling with argon, anhydrous Et2O (6 mL) was added via sy-
ringe, and the system was cooled to approximately –10 °C. Diphos-
gene (1.0 mL, 8.46 mmol, 1.21 equiv) was added dropwise via syringe,
and the solution was cooled to –20 °C. A solution of 2-chloroallyl alco-
hol (0.56 mL, 7.0 mmol, 1.0 equiv) in anhydrous Et2O (6 mL) was add-
ed dropwise via the addition funnel, and the solution was stirred at –
20 °C for an additional 15 min. The reaction was cooled to approxi-
mately –30 °C, and triethylamine (1.17 mL, 8.37 mmol, 1.20 equiv) in
anhydrous Et2O (6 mL) was added dropwise via the addition funnel,
generating a white precipitate. The reaction was then stirred for 3 h,
at which time it was allowed to warm to 23 °C. During this time, the
reaction mixture became very thick, and anhydrous Et2O (10 mL) was
added to obtain a stirable suspension. Argon was bubbled through the
suspension for 2 h to remove excess phosgene. The reaction mixture
was filtered via vacuum filtration through a fritted funnel, and the fil-
trate was concentrated by rotary evaporation under reduced pressure.
The title compound 9 (553 mg, 3.57 mmol, 51%) was obtained as a
colorless liquid. All spectroscopic data are in agreement with the lit-
erature data.11d
2-Chloroallyl 2-Oxo-1-(3-oxopentyl)cyclohexanecarboxylate (7)
Cyclohexanone (3.8 mL, 40.8 mmol, 1.0 equiv) and morpholine (6.4
mL, 73.4 mmol, 1.8 equiv) were diluted in anhydrous benzene (12
mL) in a 50 mL round-bottom flask equipped with a Dean–Stark trap
and a reflux condenser. The resulting reaction mixture was heated to
reflux until no further separation of water was observed. The volatiles
were removed by rotary evaporation under reduced pressure. The re-
sulting oily orange residue was distilled to remove excess morpholine
and afford 5.0 g (29.9 mmol, 73%) of the morpholine enamine of cy-
clohexanone as a colorless liquid.
A portion of the morpholine enamine intermediate (971 mg, 5.8
mmol, 1.8 equiv) was diluted in benzene (5 mL). Under a nitrogen at-
mosphere, 2-chloroallyl chloroformate (500 mg, 3.23 mmol, 1.0
equiv) was slowly added via syringe while the enamine solution was
stirred rapidly. After refluxing for about 10 h, the solution was cooled
to 23 °C and filtered. The solids were washed with anhydrous Et2O.
The combined filtrate and washings were returned to the reaction
flask, and 10% aqueous HCl (7 mL) was added, and the mixture was
stirred vigorously for 15–30 minutes. The layers were separated, the
aqueous layer was extracted with diethyl ether (3 ×  20 mL) and the
combined organic layers were washed with brine, dried over MgSO4,
filtered, and concentrated in vacuo. Crude 2-chloroallyl 2-oxocyclo-
hexanecarboxylate (10, 638 mg, 2.94 mmol, 91%) was used in the next
step without additional purification.
The crude β -ketoester 10 (638 mg, 2.94 mmol, 1.0 equiv) was added
to a suspension of potassium carbonate (814 mg, 5.89 mmol, 2.0
equiv) in acetone (4 mL). At 23 °C, ethyl vinyl ketone (586 μL, 5.89
mmol, 2.0 equiv) was added slowly via syringe. The resulting hetero-
geneous mixture was stirred for 7 h at 50 °C, and then cooled to 23 °C,
filtered, and the filtrate was concentrated by rotary evaporation un-
der reduced pressure. The residue was purified by flash column chro-
matography (SiO2, gradient from 15:1 to 3:1 hexanes/EtOAc) to afford
2-chloroallyl 2-oxo-1-(3-oxopentyl)cyclohexanecarboxylate (7, 676
mg, 2.24 mmol, 76%) as a colorless liquid.
TLC (SiO2): Rf = 0.56 (3:1 hexanes/EtOAc; p-anisaldehyde or KMnO4
stains).
IR (neat): 2941, 2868, 1715, 1451, 1239, 1212, 1177, 1134, 1086, 906
cm–1.
1H NMR (500 MHz, CDCl3): δ = 5.50 (s, 1 H), 5.44 (s, 1 H), 4.73 (d, J =
13.3 Hz, 1 H), 4.68 (d, J = 13.3 Hz, 1 H), 2.58–2.37 (m, 7 H), 2.16 (m,
2 H), 2.02–1.98 (m, 1 H), 1.91 (m, 2 H), 1.79–1.77 (m, 1 H), 1.67 (m,
2 H), 1.52 (m, 1 H), 1.03 (t, J = 7.3 Hz, 3 H).
13C NMR (126 MHz, CDCl3): δ = 210.4, 207.5, 171.4, 135.3, 116.5, 66.8,
60.1, 40.9, 37.3, 36.5, 35.9, 28.3, 27.4, 22.4, 7.8.
HRMS (EI+): m/z calcd for C15H22O4Cl [M + H]+: 301.1201; found:
301.1205.
(R)-2-(2-Chloroallyl)-2-(3-oxopentyl)cyclohexanone (6)
A 25 mL Schlenk flask was equipped with a magnetic stir bar and
flame-dried under vacuum. After cooling to 23 °C under anhydrous
argon, Pd2(dba)3 (4.6 mg, 5 μmol, 5 mol%) and (S)-t-BuPHOX (4.8 mg,
12.5 μmol, 12.5 mol%) were added. The flask containing the solids
was evacuated for 15 min and then refilled with dry argon. Anhy-
drous THF (3 mL) was then added and the resulting solution was
stirred at 23 °C for 30 min. At this point, 2-chloroallyl 2-oxo-1-(3-oxo-
pentyl)cyclohexanecarboxylate (7, 30 mg, 0.1 mmol, 1.0 equiv) was
added via syringe in one portion. The reaction was warmed to 30–
35 °C. When the reaction was complete as judged by TLC, the reaction
mixture was evaporated under reduced pressure and the residue was
purified by flash column chromatography (SiO2, 10:1 hexanes/EtOAc)
to afford (R)-2-(2-chloroallyl)-2-(3-oxopentyl)cyclohexanone 6 (21.7
mg, 85 μmol, 85%) as a colorless liquid. The enantiomeric composition
was determined after the aldol cyclization on compound 12.
[α]D22.5 +20.4° (c 1.04, CHCl3); TLC (SiO2): Rf = 0.42 (3:1 hexanes/EtO-
Ac; p-anisaldehyde or KMnO4 stains).
IR (neat): 2939, 2867, 1706, 1628, 1455, 1374, 1113, 889 cm–1.© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2018, 50, 4359–4368
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l.1H NMR (500 MHz, CDCl3): δ = 5.28 (app. d, J = 1.2 Hz, 1 H), 5.13 (s,
1 H), 2.70 (d, J = 14.9 Hz, 1 H), 2.63 (d, J = 14.9 Hz, 1 H), 2.51–2.42 (m,
3 H), 2.40 (q, J = 7.3 Hz, 2 H), 2.18–2.09 (m, 2 H), 1.95–1.70 (m, 7 H),
1.03 (t, J = 7.3 Hz, 3 H).
13C NMR (126 MHz, CDCl3): δ = 213.7, 210.7, 138.5, 116.8, 50.7, 43.4,
39.1, 36.7, 36.7, 36.1, 28.2, 26.9, 20.7, 7.8.
HRMS (EI+): m/z calcd for C14H22O2Cl [M + H]+: 257.1303; found:
257.1317.
(R)-4a-(2-Chloroallyl)-1-methyl-4,4a,5,6,7,8-hexahydronaphtha-
len-2(3H)-one (12)
The 1,5-diketone 6 (210 mg, 0.82 mmol, 1.0 equiv) was added to a 1 M
KOH soln (1.85 mL, 1.85 mmol, 3 equiv) in MeOH. The reaction mix-
ture was stirred at 23 °C for 7 h during which time the color gradually
changed from yellow to orange. After the reaction was complete as
judged by TLC, ca. 4 mL Et2O and ca. 4 mL H2O were added. The organ-
ic phase was separated and the aq phase was acidified by addition of
10% aq HCl (ca. 2 mL). The aq phase was extracted with Et2O (3 × 10
mL). The combined organic phases were washed with brine, dried
(MgSO4), filtered, and concentrated in vacuo. The residue was purified
by flash column chromatography (SiO2, 10:1 hexanes/EtOAc) to afford
compound 12 (142 mg, 0.59 mmol, 73%) as a colorless liquid. The en-
antiomeric excess was determined to be 88% by HPLC using chiral sta-
tionary phase columns (Chiralcel OD-H, 1% isopropanol in hexanes,
flow rate 1 mL/min, 254 nm, 10.9 min (major), 13.2 min (minor)).
[α]D21.0 –70.7° (c 0.99, CHCl3); TLC (SiO2): Rf = 0.39 (3:1 hexanes/EtO-
Ac; p-anisaldehyde or KMnO4 stains).
IR (neat): 2932, 2862, 1665, 1627, 1608, 1456, 1362, 1304, 1163,
1076, 882 cm–1.
1H NMR (500 MHz, CDCl3): δ = 5.36 (d, J = 1.0 Hz, 1 H), 5.17 (s, 1 H),
2.78 (d, J = 14.6 Hz, 1 H), 2.77–2.73 (m, 1 H), 2.62 (d, J = 14.1 Hz, 1 H),
2.62–2.54 (m, 1 H), 2.40 (ddd, J = 3.9, 4.6, 17.3 Hz, 1 H), 2.18 (ddd,
J = 3.9, 5.0, 13.9 Hz, 1 H), 2.15–2.07 (m, 1 H), 2.02 (ddd, J = 3.2, 5.4,
13.9 Hz, 1 H), 1.97–1.92 (m, 1 H), 1.78 (s, 3 H), 1.73–1.60 (m, 3 H),
1.44–1.34 (m, 1 H), 1.28 (ddd, J = 4.2, 13.5, 13.5 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 198.8, 161.2, 138.7, 129.9, 116.7, 42.1,
39.7, 38.1, 33.9, 33.1, 27.7, 26.7, 21.2, 11.1.
HRMS (EI+): m/z calcd for C14H20ClO [M + H]+: 239.1197; found:
239.1209.
(R)-4a-(2-Chloroallyl)-1-methyl-4,4a,5,6-tetrahydronaphthalen-
2(3H)-one (5)
A 20 mL glass scintillation vial was charged with a magnetic stir bar
and a solution of compound 12 (66 mg, 0.28 mmol, 1 equiv) in t-
BuOH (7.66 mL). Chloranil (205 mg, 0.84 mmol, 3 equiv) was added
and then the vial was sealed with a cap and placed in an aluminum
block preheated to 85 °C. The reaction was stirred for 2 h at which
time TLC indicated consumption of starting material. The mixture
was cooled to 22 °C and then filtered. The filtrate was concentrated in
vacuo and purified by flash chromatography (SiO2, 20:1 hexanes/EtO-
Ac) to afford the desired compound dieneone 5 as a colorless oil (19
mg, 29%).
[α]D23.4 –239.2° (c 0.026, CH2Cl2); TLC (SiO2): Rf = 0.39 (3:1 hex-
anes/EtOAc; p-anisaldehyde or KMnO4 stains).
IR (neat): 2923, 1652, 1614, 1579, 1449, 1426, 1405, 1375, 1355,
1322, 1305, 1271, 1217, 1163, 1133, 1079, 1047, 1008, 982, 900, 885,
833, 782, 754, 731, 702, 632, 611 cm–1.
1H NMR (500 MHz, CDCl3): δ = 6.50 (d, J = 9.4 Hz, 1 H), 6.25 (m, 1 H),
5.40 (s, 1 H), 5.21 (s, 1 H), 2.69 (ddd, J = 19.9, 15.0, 5.2 Hz, 1 H), 2.60
(d, J = 14.9 Hz, 1 H), 2.55–2.41 (m, 4 H), 2.33–2.16 (m, 2 H), 2.06 (dd,
J = 13.8, 5.1 Hz, 1 H), 1.83 (s, 3 H), 1.71 (td, J = 14.2, 4.8 Hz, 1 H), 1.49
(td, J = 12.8, 5.6 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 198.9, 153.6, 138.6, 136.8, 128.7,
124.6, 116.8, 41.0, 36.9, 33.9, 32.4, 32.3, 23.3, 10.3.
HRMS (EI+): m/z calcd for C14H18ClO [M + H]+: 237.1041; found:
237.1045.
Allyl 2-Oxocyclohex-3-enecarboxylate (17)
Allyl chloroformate (7.7 mL, 72 mmol, 1 equiv) was slowly added to
triethyl phosphite (12.4 mL, 72 mmol, 1 equiv) in a 250 mL round-
bottom flask. The reaction was very rapid at 23 °C, evolving heat and
emitting bubbles of chloroethane. Stirring was continued for 1 h at
23 °C, during which time bubbling ceased. The mixture was diluted
with THF (20 mL) and the crude allyl diethylphosphonoformate (16)
solution used without further purification.
In a separate flask, lithium diisopropylamide was prepared by slow
addition of n-butyllithium (2.5 M in hexanes, 26.4 mL, 66 mmol, 1.1
equiv) to a solution of diisopropylamine (10 mL, 72 mmol, 1.2 equiv)
in THF (120 mL) at –78 °C. The resulting colorless solution was stirred
for 1 h at –78 °C before a solution of freshly distilled cyclohex-2-
enone (15, 5.8 mL, 60 mmol, 1.0 equiv) in THF (20 mL) was added
slowly via cannula. The resulting yellow reaction mixture was stirred
for 1 h at –78 °C. A freshly prepared solution of allyl diethylphospho-
noformate 16 (16 g, 72 mmol, 1.2 equiv) in THF (20 mL) was added to
the reaction mixture via cannula at such a rate that the reaction tem-
perature did not exceed –70 °C. The resulting yellow reaction mixture
was stirred for an additional 1 h at –78 °C before it was allowed to
warm to 23 °C over a period of 4 h. When the reaction was complete
as judged by TLC, the reaction was quenched by the addition of satu-
rated aq NH4Cl (50 mL) at 23 °C. Most of the organic layer was evapo-
rated by rotary evaporation under reduced pressure. The mixture was
diluted with Et2O (ca. 70 mL) and the layers were separated. The
aqueous phase was extracted with Et2O (3 × 50 mL). The combined
organic layers were washed with brine, dried (MgSO4), filtered, and
concentrated in vacuo. The residue was purified by flash column
chromatography (SiO2, 3:1 hexanes/EtOAc) to afford the title com-
pound 17 (7.8 g, 43 mmol, 72%) as a colorless liquid.
TLC (SiO2): Rf =0.21 (3:1 hexanes/EtOAc; p-anisaldehyde or KMnO4
stains).
IR (neat): 3624, 3084, 3034, 2941, 2878, 1740, 1681, 1650, 1455,
1426, 1373, 1388, 1307, 1232, 1166, 1124, 1078, 1040, 1023, 994,
937, 892 cm–1.
1H NMR (500 MHz, CDCl3): δ = 7.01 (ddd, J = 3.7, 3.7, 10.3 Hz, 1 H),
6.07 (ddd, J = 1.7, 1.7, 10.0 Hz, 1 H), 5.92 (dddd, J = 5.6, 5.6, 11.2,
16.1 Hz, 1 H), 5.34 (1.5, 1.5, 1.5, 17.3 Hz, 1 H), 5.24 (dd, J = 1.2,
10.5 Hz, 1 H), 4.70–4.62 (m, 2 H), 3.46–3.43 (m, 1 H), 2.54–2.36 (m,
3 H), 2.26–2.21 (m, 1 H).
13C NMR (126 MHz, CDCl3): δ = 193.7, 169.6, 150.6, 131.7, 129.1,
118.5, 65.7, 53.4, 25.6, 24.3.
HRMS (EI+): m/z calcd for C10H12O [M]+: 180.0781; found: 180.0786.
Allyl 2-Oxo-1-(3-oxopentyl)cyclohex-3-enecarboxylate (18)
Allyl 2-oxocyclohex-3-enecarboxylate 17 (4.00 g, 22.2 mmol, 1.0
equiv) was added to a suspension of potassium carbonate (6.14 g,
44.4 mmol, 2.0 equiv) in acetone (30 mL) at 23 °C. Ethyl vinyl ketone
(4.42 mL, 44.4 mmol, 2.0 equiv) was added slowly via syringe. The re-© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2018, 50, 4359–4368
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l.sulting heterogeneous mixture was stirred for 2.5 h at 50 °C, then
cooled to 23 °C, filtered, and the filtrate was concentrated by rotary
evaporation under reduced pressure. The residue was purified by
flash column chromatography (SiO2, hexanes–EtOAc 5:1 to 3:1) to af-
ford allyl 2-oxo-1-(3-oxopentyl)cyclohex-3-enecarboxylate 18 (4.77
g, 18.0 mmol, 82%) as a colorless liquid.
TLC (SiO2): Rf = 0.19 (3:1 hexanes/EtOAc; p-anisaldehyde or KMnO4
stains).
IR (neat): 3085, 3035, 2975, 2939, 1731, 1716, 1682, 1449, 1452,
1387, 1376, 1354, 1237, 1221, 1188, 1116, 1094, 993, 974, 943 cm–1.
1H NMR (500 MHz, CDCl3): δ = 6.92–6.88 (m, 1 H), 6.03 (ddd, J = 1.9,
1.9, 10.0 Hz, 1 H), 5.90–5.82 (m, 1 H), 5.31–5.27 (m, 1 H), 4.64–4.57
(m, 2 H), 2.61–2.50 (m, 1 H), 2.49–2.37 (m, 6 H), 2.20–2.14 (m, 1 H),
2.07–2.01 (m, 1 H), 1.97–1.92 (m, 1 H), 1.04 (t, J = 7.3 Hz, 3 H).
13C NMR (126 MHz, CDCl3): δ = 210.5, 196.1, 171.3, 149.2, 131.5,
129.1, 118.6, 65.8, 56.2, 37.6, 35.9, 31.0, 27.3, 23.5, 7.8.
HRMS (EI+): m/z calcd for C15H20O4 [M]+: 264.1356; found: 264.1347.
(R)-6-Allyl-6-(3-oxopentyl)cyclohex-2-enone (19)
A 500 mL round-bottom flask was equipped with a magnetic stir bar
and then flame-dried under vacuum. After cooling to 23 °C under dry
argon, Pd2(dba)3 (260 mg, 0.28 mmol, 2.5 mol%) and (S)-t-BuPHOX
(275 mg, 0.71 mmol, 6.25 mol%) were added. The flask containing the
solids was evacuated for 15 min and then refilled with dry argon. An-
hydrous THF (342 mL) was then added and the resulting solution
stirred at 23 °C for 30 min. At this point, allyl 2-oxo-1-(3-oxopen-
tyl)cyclohex-3-enecarboxylate 18 (3.00 g, 11.4 mmol, 1.0 equiv) was
added via syringe in one portion. The reaction was warmed to 30 °C.
When the reaction was complete as judged by TLC, the reaction mix-
ture was evaporated under reduced pressure and the residue was pu-
rified by flash column chromatography (SiO2, hexanes/EtOAc, 10:1) to
afford (R)-6-allyl-6-(3-oxopentyl)cyclohex-2-enone 19 (2.19 g, 10.0
mmol, 88%) as a colorless liquid. The enantiomeric excess was deter-
mined to be 83% by SFC using chiral stationary phase columns (Chi-
ralcel OD-H, 5% isopropanol in hexanes, flow rate 1 mL/min, 244 nm,
5.5 min (minor), 5.8 min (major)).
[α]D20.9 +13.9° (c 1.09, CHCl3, 83% ee); TLC (SiO2): Rf = 0.25 (3:1 hex-
anes/EtOAc; p-anisaldehyde or KMnO4 stains).
IR (neat): 3075, 3033, 2976, 2935, 1714, 1670, 1449, 1430, 1387,
1221, 1115, 997, 916 cm–1.
1H NMR (500 MHz, CDCl3): δ = 6.87 (ddd, J = 3.9, 3.9, 10.0 Hz, 1 H),
5.90 (ddd, J = 2.0, 2.0, 10.0 Hz, 1 H), 5.73–5.65 (m, 1 H), 5.09–5.05 (m,
2 H), 2.46–2.27 (m, 7 H), 2.20 (dd, J = 7.8, 13.9 Hz, 1 H), 1.93–1.75 (m,
4 H), 1.03 (t, J = 7.3 Hz, 3 H).
13C NMR (126 MHz, CDCl3): δ = 211.2, 202.6, 148.9, 133.5, 128.7,
118.4, 46.8, 38.8, 36.7, 36.0, 31.1, 27.6, 22.9, 7.8.
HRMS (EI+): m/z calcd for C14H20O2 [M]+: 220.1458; found: 220.1487.
(R)-2-(2-Oxo-1-(3-oxopentyl)cyclohex-3-enyl)acetaldehyde (14)
A 500 mL round-bottom flask equipped with a stir bar was charged
with enone 19 (2.19 g, 10.0 mmol, 1.0 equiv), pyridine (899 μL, 11.1
mmol, 1.12 equiv), and MeOH (331 mL). A small portion of Sudan Red
7B (5 mg) was added as an indicator to determine the end point of the
ozonolysis (upon completion reaction with indicator turns from col-
orless to red/pink). A flow of ozone (125 mL/min oxygen flow, 302
mg/h) was passed through the solution until there was no starting
material left by TLC analysis. The reaction flask was purged with ni-
trogen. Trimethyl phosphite (7.3 mL, 49.6 mmol, 5.0 equiv) was add-
ed via syringe, and the flask was allowed to slowly warm to 23 °C. Af-
ter stirring at 23 °C for 1 h, the reaction mixture was concentrated in
vacuo and the residue was purified by flash column chromatography
(SiO2, 5:1 hexanes/EtOAc) to afford the title compound 14 (1.83 g,
8.25 mmol, 83%) as a colorless liquid.
[α]D20.9 +36.6° (c 1.04, CHCl3).
TLC (SiO2): Rf =0.18 (3:1 hexanes/EtOAc; p-anisaldehyde or KMnO4
stains).
IR (neat): 2975, 2938, 2737, 1714, 1668, 1455, 1389, 1223, 1112, 940,
807 cm–1.
1H NMR (500 MHz, CDCl3): δ = 9.71 (m, 1 H), 6.94–6.91 (m, 1 H), 5.97
(ddd, J = 1.5, 2.4, 10.1 Hz, 1 H), 2.83 (dd, J = 1.5, 16.2 Hz, 1 H), 2.56–
2.49 (m, 1 H), 2.45–2.31 (m, 6 H), 2.18 (dq, J = 5.4, 13.8 Hz, 1 H), 2.00
(dq, J = 5.4, 15.1 Hz, 1 H), 1.91–1.81 (m, 2 H), 1.03 (t, J = 7.3 Hz, 3 H).
13C NMR (126 MHz, CDCl3): δ = 210.2, 201.2, 200.9, 149.4, 128.1, 48.1,
46.1, 36.5, 36.1, 31.7, 27.5, 22.8, 7.8.
HRMS (EI+): m/z calcd for C13H18O3 [M]+: 222.1250; found: 222.1233.
(6R)-9-Ethyl-9-hydroxyspiro[5.5]undec-2-ene-1,8-dione (20)
A 25 mL round-bottom flask was charged with a stir bar and CH2Cl2 (5
mL). The aldehyde 14 (100 mg, 0.45 mmol, 1.0 equiv), 2-(perfluoro-
phenyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium tetrafluo-
roborate 23 (124 mg, 0.45 mmol, 1.0 equiv), and triethylamine (63 μL,
0.45 mmol, 1.0 equiv) were added consecutively. The resulting yellow
mixture was stirred at 45 °C for 2 h. After cooling to 23 °C, the reac-
tion mixture was concentrated in vacuo and the residue was purified
by flash column chromatography (SiO2, 2:1 hexanes/EtOAc) to afford
the title compound 20 (74 mg, 0.33 mmol, 74%) as a colorless liquid
comprising a 1:1 mixture of diastereomers.
TLC (SiO2): Rf = 0.18 (3:1 hexanes/EtOAc; p-anisaldehyde or KMnO4
stains).
IR (neat): 3477, 2956, 2938, 2922, 2877, 1710, 1672, 1463, 1386,
1259, 1218, 1155, 1132, 1023, 803 cm–1.
1H NMR (500 MHz, CDCl3): δ = 6.96–6.92 (m, 1 H), 6.01 (ddd, J = 2.0,
2.0, 10.3 Hz, 1 H), 3.89 (s, 1 H), 3.15 (d, J = 13.9, 1 H), 2.39–2.36 (m,
2 H), 2.23–2.16 (m, 2 H), 2.03–1.76 (m, 6 H), 1.71 (dddd, J = 7.3, 7.3,
7.3, 14.3 Hz, 1 H), 0.81 (t, J = 7.3 Hz, 3 H).
13C NMR (126 MHz, CDCl3): δ = 213.8, 199.7, 149.5, 128.1, 78.6, 50.0,
43.6, 35.6, 30.2, 29.3, 27.1, 22.6, 7.0.
HRMS (EI+): m/z calcd for C13H19O3 [M + H]+: 223.1329; found:
223.1336.
(1R, 4S)-1-(3-Oxopentyl)bicyclo[2.2.2]octane-2,5-dione (13)
1,1′-Azobis(cyclohexanecarbonitrile) (V-40) (2.47 g, 10.1 mmol, 1.5
equiv) was added to a solution of the alkenal 14 (1.50 g, 6.75 mmol,
1.0 equiv) and t-dodecanethiol (4.76 mL, 20.2 mmol, 3.0 equiv) in an-
hydrous toluene (68 mL). The solution was degassed three times by
the freeze-thaw procedure. The reaction mixture was then heated at
reflux under argon atmosphere for 24 h. After cooling to 23 °C, the
solvents were evaporated under reduced pressure. The residue was
purified by flash column chromatography (SiO2, gradient from 3:1 to
1:1 hexanes/EtOAc) to afford bicyclo[2.2.2]octadione 13 (1.17 g, 5.26
mmol, 78%) as a white solid.
Mp 73 °C; [α]D19.7 +29.3° (c 0.99, CHCl3); TLC (SiO2): Rf = 0.10 (3:1 hex-
anes/EtOAc; p-anisaldehyde or KMnO4 stains).
IR (neat): 2940, 2879, 1720, 1450, 1399, 1115, 1086, 952 cm–1.
1H NMR (500 MHz, CDCl3): δ = 2.74 (quint, J = 2.9 Hz, 1 H), 2.53–2.33
(m, 8 H), 2.09–2.03 (m, 1 H), 1.98–1.91 (m, 1 H), 1.86–1.69 (m, 4 H),
1.05 (t, J = 7.3 Hz, 3 H).© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2018, 50, 4359–4368
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l.13C NMR (126 MHz, CDCl3): δ = 211.7, 211.0, 210.6, 48.7, 44.8, 44.3,
40.7, 37.0, 35.9, 28.0, 26.8, 22.6, 7.8.
HRMS (EI+): m/z calcd for C13H18O3 [M]+: 222.1250; found: 222.1254.
(2S,4aR)-2,8-Dimethyl-1,2,5,6-tetrahydro-7H-2,4a-ethanonaph-
thalene-3,7(4H)-dione (21)
The 1,5-diketone 13 (1.75 g, 7.87 mmol, 1.0 equiv) was added to 1 M
KOH (11.8 mL, 11.8 mmol, 1.5 equiv) in MeOH (33 mL). The reaction
mixture was stirred at 23 °C for 7 h during which time the color grad-
ually changed to orange. After the reaction was complete as judged by
TLC, the reaction mixture was concentrated in vacuo. Subsequently,
the residue was redissolved in Et2O (30 mL) and H2O (30 mL). The or-
ganic phase was separated and the aqueous phase was then acidified
by addition of 10% aq HCl (ca. 12 mL) before it was extracted with
Et2O (3 × 30 mL). The combined organic phases were washed with
brine, dried (MgSO4), filtered, and concentrated in vacuo. The residue
was purified by flash column chromatography (SiO2, 3:1 hex-
anes/EtOAc). The colorless solid material was recrystallized from hex-
anes to afford 21 (1.31 g, 6.41 mmol, 81%) as colorless crystals suit-
able for X-ray analysis. The enantiomeric excess was determined to be
99% with HPLC using chiral stationary phase columns (Chiralpak AD,
10% isopropanol in hexanes, flow rate 1 mL/min, 254 nm, 13.3 min
(major), 14.7 min (minor)).
Mp 110 °C; [α]D20.0 +30.5° (c 1.00, CHCl3, >99% ee); TLC (SiO2):
Rf = 0.13 (3:1 hexanes/EtOAc; p-anisaldehyde or KMnO4 stains).
IR (neat): 2966, 2952, 2915, 1720, 1660, 1631, 1472, 1402, 1310,
1295, 1124, 889, 867, 709 cm–1.
1H NMR (500 MHz, CDCl3): δ = 2.65 (s, 2 H), 2.62 (t, J = 2.7 Hz, 1 H),
2.46–2.42 (m, 2 H), 2.37 (dd, J = 2.7, 18.7 Hz, 1 H), 2.23 (d, J = 18.5 Hz,
1 H), 2.01–1.96 (m, 2 H), 1.90–1.84 (m, 3 H), 1.72 (s, 3 H), 1.64–1.59
(m, 1 H).
13C NMR (126 MHz, CDCl3): δ = 213.5, 197.3, 157.2, 130.3, 48.4, 43.7,
38.2, 33.5, 32.4, 31.7, 29.9, 23.1, 10.6.
HRMS (EI+): m/z calcd for C13H16O2 [M]+: 204.1145; found: 204.1114.
(2S,4aR)-2,8-Dimethyl-3-methylene-1,2,3,4,5,6-hexahydro-7H-
2,4a-ethanonaphthalen-7-one (4)
A 25 mL round-bottom flask was charged with methyltriphenylphos-
phonium bromide (879 mg, 2.46 mmol, 1.5 equiv) and THF (8 mL).
The solution was cooled to 0 °C and a solution of potassium t-butox-
ide (221 mg, 1.97 mmol, 1.2 equiv) in THF (2 mL) was slowly added
via syringe. The solution was stirred at 0 °C for 15 min before a solu-
tion of dione 21 (335 mg, 1.64 mmol, 1.0 equiv) in THF (2 mL) was
added via syringe. Upon addition the color of the reaction mixture
changed from yellow to red/brown. Stirring was continued, first at
0 °C for 30 min, then at 23 °C for another 30 min. The reaction was
quenched by addition of saturated aq NH4Cl (7 mL) and Et2O (7 mL).
The layers were separated and the aqueous layer was extracted with
Et2O (3 × 10 mL). The combined organic layers were washed with
brine (5 mL), dried (MgSO4), filtered, and concentrated in vacuo. The
residue was purified by flash column chromatography (SiO2, 7:1 hex-
anes/EtOAc) to afford enone 4 (295 mg, 1.45 mmol, 89%) as a colorless
liquid.
[α]D23.4 +21.9° (c 2.4, CH2Cl2); TLC (SiO2): Rf =0.24 (3:1 hexanes/EtOAc;
p-anisaldehyde or KMnO4 stains).
IR (neat): 3069, 2928, 2870, 2823, 1666, 1630, 1449, 1308, 1198,
1082, 881, 754 cm–1.
1H NMR (500 MHz, CDCl3): δ = 4.83 (s, 1 H), 4.64 (s, 1 H), 2.52 (d,
J = 2.4 Hz, 1 H), 2.45–2.30 (m, 5 H), 2.22 (d, J = 16.7 Hz, 1 H), 1.81–
1.68 (m, 4 H), 1.65 (s, 3 H), 1.61 (m, 1 H), 1.47 (m, 1 H).
13C NMR (126 MHz, CDCl3): δ = 198.2, 182.2, 149.2, 129.0, 106.4, 40.2,
37.0, 36.4, 35.7, 33.8, 32.2, 30.7, 26.4, 10.3.
HRMS (EI+): m/z calcd for C14H18O [M]+: 202.1352; found: 202.1351.
(2S,4aR,8R,8aS)-8-Allyl-8-methyl-3-methyleneoctahydro-7H-2,4a-
ethanonaphthalen-7-one (22) and (2S,4aR,8R,8aS)-8-Allyl-8-meth-
yl-3-methyleneoctahydro-7H-2,4a-ethanonaphthalen-7-one (23)
A 20 mL glass scintillation vial (equipped with a magnetic stir bar)
pre-cooled to –78 °C in a dry-ice/acetone bath was charged with
freshly condensed ammonia (6.64 mL) and metallic Li (11.5 mg, 1.66
mmol, 4 equiv). The resulting mixture turned dark blue within 1 min
and was allowed to stir at –78 °C for 10 min. A solution of dienone 4
(84 mg, 0.415 mmol, 1 equiv) in THF (1.66 mL) and H2O (7.5 μL, 0.415
mmol, 1 equiv) was then added to the dark-blue reaction mixture and
the mixture was then allowed to warm to –40 °C by replacing the dry-
ice/acetone bath with a dry-ice/acetonitrile bath. After stirring for 1 h
at –40 °C, a portion of isoprene (116 μL, 1.66 mmol, 4 equiv) was add-
ed and reaction immediately turned clear and colorless. The reaction
mixture was then cooled to –78 °C by replacing the dry-ice/acetoni-
trile bath with a dry-ice/acetone bath, and after 10 min at this tem-
perature a portion of allyl bromide (144 μL, 1.66 mmol, 4 equiv) was
added in one portion. After 1.5 h, TLC indicated complete consump-
tion of the intermediates and the reaction was quenched with deion-
ized H2O (9 mL) and was allowed to warm to r.t. (23 °C). The crude
mixture was then transferred to a 500 mL separatory funnel and di-
luted with 1 M aq HCl soln (ca. 30 mL, until pH 7–9), deionized H2O
(100 mL), aq NH4Cl soln (100 mL), and EtOAc (60 mL). The aqueous
phase was separated and then extracted with EtOAc (3 × 30 mL, mon-
itored by TLC). The combined organic phases were dried over Na2SO4,
decanted, and concentrated in vacuo. Purification by flash chroma-
tography (SiO2, 30:1 hexanes/EtOAc) afforded the compounds 22 and
23 as 1:1 mixture of inseparable diastereomers that appear as a color-
less oil (27 mg, 27%).
TLC (SiO2): Rf = 0.32 (10:1 hexanes/EtOAc; p-anisaldehyde or KMnO4
stains).
IR (neat): 3069, 2926, 2863, 1711, 1647, 1450, 1429, 1377, 1314,
1279, 1222, 1059, 1059, 1002, 973, 911, 874, 916, 728, 565 cm–1.
1H NMR (500 MHz, CDCl3): δ = 5.76–5.59 (m, 1 H), 4.98 (dd, J = 18.4,
9.2 Hz, 2 H), 4.80 (dd, J = 4.2, 2.0 Hz, 1 H), 4.62 (dd, J = 10.4, 1.8 Hz,
1 H), 2.77 (d, J = 17.3 Hz, 0.4 H), 2.57 (dddd, J = 13.8, 11.1, 5.2, 2.5 Hz,
1 H), 2.44 (dd, J = 13.8, 5.3 Hz, 1 H), 2.34 (s, 1 H), 2.28–2.18 (m, 1 H),
2.18–1.95 (m, 2.5 H), 1.86 (ddd, J = 31.3, 16.7, 9.7 Hz, 2.5 H), 1.76–
1.58 (m, 5 H), 1.58–1.50 (m, 1.5 H), 1.46 (ddd, J = 12.7, 8.1, 1.9 Hz,
1 H), 1.43–1.33 (m, 1 H), 1.32–1.18 (m, 2.5 H), 1.14 (d, J = 11.8 Hz,
2 H), 1.06 (s, 1 H), 1.01–0.76 (m, 1 H).
13C NMR (126 MHz, CDCl3): δ = 216.1, 151.3, 150.9, 135.2, 135.1,
117.2, 117.1, 106.0, 105.1, 77.3, 77.0, 76.8, 50.8, 46.1, 42.3, 41.5, 41.4,
41.3, 37.5, 36.9, 36.3, 36.1, 35.6, 34.9, 32.6, 32.5, 28.1, 28.0, 27.9, 26.7,
25.8, 20.5.
HRMS (EI+): m/z calcd for C17H24O [M + H]+: 245.1900; found:
245.1900.© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2018, 50, 4359–4368
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l.(2S,4aS,8S,8aR)-8-Allyl-8-methyl-3-methylene-1,2,3,4,8,8a-hexa-
hydro-7H-2,4a-ethanonaphthalen-7-one (3) and (2S,4aS,8S,8aS)-8-
Allyl-8-methyl-3-methylene-1,2,3,4,8,8a-hexahydro-7H-2,4a-eth-
anonaphthalen-7-one (24)
A 4 mL glass scintillation vial (equipped with a magnetic stir bar) was
charged with a solution of the diastereomeric mixture of compounds
22 and 23 (10 mg, 0.041 mmol, 1 equiv) in CH2Cl2 (0.1 mL) and placed
in an ice bath. After stirring for 5 min, a portion of Et3N (11.4 μL, 0.082
mmol, 2 equiv) was added, followed by TMSOTf (9 μL, 0.049 mmol,
1.2 equiv). The reaction mixture was allowed to stir at 0 °C for 30 min,
and then a portion of NBS (8.7 mg, 0.049 mmol, 1.2 equiv) was added.
After 50 min, TLC indicated complete consumption of starting materi-
al and the reaction was quenched with aq NH4Cl soln (2 mL) and hex-
anes (2 mL). The aqueous phase was separated and then extracted
with hexanes (1 × 2 mL). The combined organic phases were dried
over Na2SO4, decanted, and concentrated in vacuo. Purification by
flash chromatography (SiO2, 20:1 hexanes/EtOAc) afforded a crude
mixture of diastereomeric monobromides. This mixture was trans-
ferred to a 4 mL glass vial (equipped with a magnetic stir bar) and dis-
solved in DMF (0.2 mL), followed by addition of Li2CO3 (6 mg, 0.082
mmol, 2 equiv) and LiBr (3.6 mmol, 0.041 mmol, 1 equiv). The vial
was then sealed with a cap and placed in an aluminum block preheat-
ed to 130 °C. The reaction was stirred for 1 h at which time TLC indi-
cated consumption of starting material. The mixture was cooled to
22 °C, quenched with aq NH4Cl soln (3 mL) and hexanes (2 mL). The
aqueous phase was separated and then extracted with hexanes (3 × 2
mL, monitored by TLC). The combined organic phases were dried over
Na2SO4, decanted, and concentrated in vacuo. Purification by flash
chromatography (SiO2, 30:1 hexanes/EtOAc) afforded the desired
compound 3 (3.1 mg, 32%) along with its diastereomer 24 (3.0 mg,
31%), each as colorless oils.
Analytical Data for 3
[α]D23.6 +58° (c 0.1, CH2Cl2); TLC (SiO2): Rf = 0.27 (10:1 hexanes/EtOAc;
p-anisaldehyde or KMnO4 stains).
IR (neat): 3071, 2926, 2866, 1674, 1557, 1454, 1430, 1389, 1374,
1280, 1248, 1228, 1177, 1153, 1120, 1073, 1001, 911, 880, 826, 766,
723, 708, 647, 577cm–1.
1H NMR (500 MHz, CDCl3): δ = 6.47 (d, J = 10.1 Hz, 1 H), 5.85 (d,
J = 10.1 Hz, 1 H), 5.63 (dtd, J = 14.9, 9.8, 5.1 Hz, 1 H), 5.00 (dd, J = 28.2,
13.6 Hz, 2 H), 4.83 (s, 1 H), 4.66 (d, J = 1.6 Hz, 1 H), 2.65 (dd, J = 13.9,
5.0 Hz, 1 H), 2.40 (d, J = 2.7 Hz, 1 H), 2.28 (d, J = 16.1 Hz, 1 H), 2.07 (d,
J = 17.0 Hz, 2 H), 1.92 (dd, J = 13.8, 9.6 Hz, 2 H), 1.77–1.62 (m, 3 H),
1.49 (dd, J = 14.3, 7.8 Hz, 3 H), 1.13 (s, 3 H).
13C NMR (126 MHz, CDCl3): δ = 204.3, 154.7, 149.1, 134.8, 126.3,
117.2, 106.9, 48.0, 44.3, 40.0, 39.6, 36.0, 29.7, 27.7, 26.7, 26.1, 20.7.
HRMS (EI+): m/z calcd for C17H22O [M + H]+: 243.1743; found:
243.1750.
Analytical Data for 24
[α]D23.6 +114° (c 0.1, CH2Cl2); TLC (SiO2): Rf = 0.31 (10:1 hexanes/EtO-
Ac; p-anisaldehyde or KMnO4 stains).
IR (neat): 3071, 2930, 2864, 1673, 1456, 1430, 1388, 1374, 1333,
1276, 1245, 1193, 1174, 1117, 1104, 1053, 1000, 976, 909, 872, 826,
770, 723, 710, 648, 567 cm–1.
1H NMR (500 MHz, CDCl3): δ = 6.46 (d, J = 10.1 Hz, 1 H), 5.85 (d,
J = 10.1 Hz, 1 H), 5.67 (dddd, J = 19.9, 14.8, 9.9, 4.8 Hz, 1 H), 5.03 (dd,
J = 29.0, 13.6 Hz, 2 H), 4.83 (d, J = 1.6 Hz, 1 H), 4.63 (d, J = 1.7 Hz, 1 H),
2.71–2.60 (m, 2 H), 2.39 (s, 1 H), 2.22–2.11 (m, 2 H), 1.90 (dd, J = 13.8,
9.8 Hz, 1 H), 1.81–1.73 (m, 1 H), 1.69 (dd, J = 8.4, 5.7 Hz, 2 H), 1.48 (dt,
J = 13.0, 8.1 Hz, 2 H), 1.40 (ddd, J = 12.8, 8.5, 3.7 Hz, 1 H), 1.07 (s, 3 H).
13C NMR (126 MHz, CDCl3): δ = 204.3, 154.5, 149.4, 135.1, 126.2,
117.1, 105.6, 47.9, 39.9, 38.4, 36.0, 35.9, 35.6, 29.7, 26.8, 25.7, 20.9.
HRMS (EI+): m/z calcd for C17H22O [M + H]+: 243.1743; found:
243.1756.
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